Teva Pharmaceutical Industries Ltd (TEVA) VP Sells $58,940.72 in Stock

Share on StockTwits

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) VP Richard Daniell sold 2,488 shares of the business’s stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $23.69, for a total transaction of $58,940.72. Following the transaction, the vice president now directly owns 2,488 shares in the company, valued at approximately $58,940.72. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Richard Daniell also recently made the following trade(s):

  • On Monday, September 10th, Richard Daniell sold 696 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $21.25, for a total transaction of $14,790.00.

Shares of TEVA stock traded up $0.93 during trading hours on Friday, reaching $21.38. 11,356,427 shares of the stock were exchanged, compared to its average volume of 12,954,213. The company has a debt-to-equity ratio of 1.86, a quick ratio of 0.69 and a current ratio of 1.03. Teva Pharmaceutical Industries Ltd has a 12-month low of $10.85 and a 12-month high of $25.96. The firm has a market capitalization of $21.90 billion, a price-to-earnings ratio of 5.44, a PEG ratio of 1.61 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, August 2nd. The company reported $0.78 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.64 by $0.14. Teva Pharmaceutical Industries had a negative net margin of 47.98% and a positive return on equity of 19.92%. The firm had revenue of $4.70 billion for the quarter, compared to analyst estimates of $4.75 billion. During the same period in the prior year, the firm earned $1.02 earnings per share. The business’s quarterly revenue was down 17.8% compared to the same quarter last year. Equities analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.68 EPS for the current fiscal year.

Several analysts recently issued reports on TEVA shares. Mizuho boosted their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $29.00 and gave the company a “buy” rating in a report on Monday, September 17th. Wells Fargo & Co set a $23.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Monday, September 17th. Jefferies Financial Group restated a “hold” rating and issued a $21.00 price objective on shares of Teva Pharmaceutical Industries in a report on Friday, August 3rd. Goldman Sachs Group boosted their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company a “buy” rating in a report on Monday, June 25th. Finally, Cantor Fitzgerald set a $25.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a report on Friday, September 14th. Six equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $21.68.

Several hedge funds have recently added to or reduced their stakes in TEVA. PointState Capital LP purchased a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth approximately $161,826,000. Point72 Asset Management L.P. purchased a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth approximately $90,746,000. Renaissance Technologies LLC increased its stake in shares of Teva Pharmaceutical Industries by 348.1% during the second quarter. Renaissance Technologies LLC now owns 4,036,863 shares of the company’s stock worth $98,177,000 after buying an additional 3,135,900 shares during the period. Caisse DE Depot ET Placement DU Quebec boosted its holdings in Teva Pharmaceutical Industries by 116.1% in the second quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,354,508 shares of the company’s stock valued at $57,262,000 after purchasing an additional 1,264,900 shares in the last quarter. Finally, OppenheimerFunds Inc. boosted its holdings in Teva Pharmaceutical Industries by 15.5% in the first quarter. OppenheimerFunds Inc. now owns 4,229,508 shares of the company’s stock valued at $72,282,000 after purchasing an additional 566,300 shares in the last quarter. Hedge funds and other institutional investors own 64.51% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Read More: Why do companies issue stock splits?

Insider Buying and Selling by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply